Exelixis Inc (EXEL) 5.40 $EXEL
Exelixis, Inc. Earnings: Riding the Meteor
Brian Orelli, The Motley Fool - Motley Fool - 12 mins ago
Exelixis reported earnings on Tuesday, and as usual, the pipeline was much more important for the biotech than its revenue and profit. Exelixis results: The raw numbers Metric Q3 2015 Actuals Q3 2014 Actuals Growth (YOY)...
MRK: 53.03 (unch), BMY: 64.15 (+0.43), EXEL: 5.40 (-0.01)
6 Stocks That Could Double In 2016
Matthew Frankel, Selena Maranjian, Sean Williams, Dan Caplinger, Jason Hall, and Cheryl Swanson, The Motley Fool - Motley Fool - Sat Nov 14, 2:00PM CST
Source: 401kcalculator.org via Flickr . As long as most of your money is invested in high-quality, stable companies, there's absolutely nothing wrong with doing some speculating on companies with massive potential for gains. With that in mind,...
DDD: 8.75 (+0.23), CLF: 2.72 (-0.29), LL: 13.87 (-1.03), TWTR: 25.18 (-0.95), GTLS: 19.36 (+0.18), EXEL: 5.40 (-0.01)
Are Investors Nuts To Be Short These Stocks?
Todd Campbell, The Motley Fool - Motley Fool - Sat Nov 14, 8:01AM CST
Source: Flickr user stockmonkeys.com Healthcare stocks are among the most heavily shorted stocks on the market and the number of shares held short relative to shares outstanding for these three companies is downright stratospheric. Because...
ZIOP: 12.94 (-0.17), EXEL: 5.40 (-0.01), ATHN: 161.21 (-0.88)
Exelixis to Present at the Stifel 2015 Healthcare Conference on Tuesday, November 17
Business Wire - Thu Nov 12, 3:35PM CST
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company's president and chief executive officer, will provide an overview of the company at Stifel's 2015 Healthcare Conference, taking place November 17-18 in New York. The Exelixis presentation is scheduled for 3:00 PM EST/12:00 PM PST on Tuesday, November 17, 2015.
EXEL: 5.40 (-0.01)
Exelixis (EXEL) Stock Dropped Following Earnings Release
at The Street - Wed Nov 11, 3:23PM CST
Exelixis (EXEL) shares closed trading down nearly double digits following mixed third quarter earnings results.
EXEL: 5.40 (-0.01)
Why Exelixis Shares Declined Today
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 11, 11:16AM CST
Source: Exelixis What: After reporting third quarter financials and receiving an FDA green light for a key drug prospect, shares in Exelixis slipped by up to 10% earlier today. So what: Exelixis has one drug on the market, and...
EXEL: 5.40 (-0.01)
The Zacks Analyst Blog Highlights: Gilead Sciences, Retrophin, Exelixis, Actelion and Enzo Biochem
Zacks Equity Research - Zacks Investment Research - Wed Nov 11, 8:30AM CST
The Zacks Analyst Blog Highlights: Gilead Sciences, Retrophin, Exelixis, Actelion and Enzo Biochem
ENZ: 4.50 (+0.14), GILD: 102.57 (-1.66), RTRX: 18.72 (+0.42), EXEL: 5.40 (-0.01)
Exelixis (EXEL) Stock Declines in After-Hours Trading on Quarterly Loss
at The Street - Tue Nov 10, 3:59PM CST
Exelixis (EXEL) stock is falling in after-hours trading after the company reported a wider than expected loss for the 2015 third quarter.
EXEL: 5.40 (-0.01)
Exelixis reports 3Q loss
Automated Insights - Tue Nov 10, 3:46PM CST
SOUTH SAN FRANCISCO, Calif. (AP) _ Exelixis Inc. (EXEL) on Tuesday reported a loss of $47.6 million in its third quarter.
EXEL: 5.40 (-0.01)
Exelixis Announces Third Quarter 2015 Financial Results and Provides Corporate Update
Business Wire - Tue Nov 10, 3:27PM CST
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2015 and provided an update on progress toward delivering upon its key 2015 corporate objectives and clinical development milestones.
EXEL: 5.40 (-0.01)
Daiichi Sankyo and Plexxikon Announce FDA Approval of Cobimetinib in Combination with Zelboraf® (vemurafenib) in Advanced Melanoma
PR Newswire - Tue Nov 10, 3:11PM CST
Daiichi Sankyo, Inc. and Plexxikon Inc., a member of the Daiichi Sankyo Group, today announced the U.S. Food and Drug Administration (FDA) approved cobimetinib, developed by Genentech, a member of the Roche Group, and Exelixis Inc., for the treatment of people with BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma in combination with Zelboraf® (vemurafenib). Cobimetinib and Zelboraf are not used to treat melanoma with a normal BRAF gene. Cobimetinib in combination with Zelboraf will be co-promoted in the United States by Genentech, Daiichi Sankyo, Inc. and Exelixis. Cobimetinib will be available within two weeks.
EXEL: 5.40 (-0.01)
FDA Approves COTELLIC(TM) (Cobimetinib) for use in Combination with Vemurafenib to Treat Advanced Melanoma
Business Wire - Tue Nov 10, 12:37PM CST
--COTELLIC is expected to be available in the U.S. within two weeks -
EXEL: 5.40 (-0.01)
5 Biotech Stocks with Good Growth Prospects
Swarup Gupta - Zacks Investment Research - Tue Nov 10, 9:35AM CST
A variety of factors indicate that the growth potential for the sector remains undiminished
ENZ: 4.50 (+0.14), GILD: 102.57 (-1.66), SHPG: 203.58 (-2.36), UNH: 111.41 (-1.41), RTRX: 18.72 (+0.42), AMGN: 151.55 (+0.57), DYAX: 34.42 (+0.03), EXEL: 5.40 (-0.01)
What to Expect from Exelixis (EXEL) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Nov 09, 2:50PM CST
Will Exelixis (EXEL) pull a surprise this earnings season?
AFMD: 6.04 (-0.21), CXRX: 33.10 (+4.56), EXEL: 5.40 (-0.01)
The Zacks Analyst Blog Highlights: Amazon.com, LendingTree, Dycom Industries, Exelixis and ZIOPHARM Oncology
Zacks Equity Research - Zacks Investment Research - Thu Nov 05, 8:30AM CST
The Zacks Analyst Blog Highlights: Amazon.com, LendingTree, Dycom Industries, Exelixis and ZIOPHARM Oncology
AMZN: 642.35 (-23.25), ZIOP: 12.94 (-0.17), TREE: 116.49 (-2.51), DY: 81.82 (-1.10), EXEL: 5.40 (-0.01)
5 Stocks That Doubled in 2015 -- And Keep Going Up
Zacks Equity Research - Zacks Investment Research - Wed Nov 04, 3:12PM CST
Despite the adversities playing spoilsport, there are a few stocks that have not only held the fort but have also crushed market estimates in 2015.
AMZN: 642.35 (-23.25), ZIOP: 12.94 (-0.17), TREE: 116.49 (-2.51), DY: 81.82 (-1.10), EXEL: 5.40 (-0.01)
Covered Call Alerts For Ambarella, Exelixis, Electronic Arts, Nabors Industries and Whole Foods Market Released By InvestorsObserver
PR Newswire - Wed Nov 04, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for AMBA, EXEL, EA, NBR and WFM.
WFM: 29.55 (-0.36), AMBA: 50.35 (-2.04), EA: 69.89 (-1.77), NBR: 9.25 (+0.03), EXEL: 5.40 (-0.01)
3 Biotech Stocks to Buy in November
Brian Feroldi, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Sun Nov 01, 12:20PM CST
Image Source TBIT via pixabay Well, that was fast. A month ago it seemed like biotech stocks couldn't do anything right. Shares of the iShares Nasdaq Biotechnology ETF , which holds a huge collection of biotech stocks, were pummeled over fears...
SGYP: 5.92 (+0.03), IRWD: 11.87 (+0.43), ALXN: 166.44 (+0.31), IBB: 323.64 (+3.53), EXEL: 5.40 (-0.01)
United Therapeutics Beats on Q3 Earnings, Revenues
Arpita Dutt - Zacks Investment Research - Wed Oct 28, 11:18AM CDT
United Therapeutics' (UTHR) third quarter results were better-than-expected with the company's products performing well.
MDT: 74.46 (+0.25), UTHR: 146.79 (+0.65), AMGN: 151.55 (+0.57), EXEL: 5.40 (-0.01)
Agenus Q3 Loss Wider than Expected, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Wed Oct 28, 10:50AM CDT
Agneus (AGEN) reported wider-than-expected loss.
AGEN: 4.63 (+0.11), AMGN: 151.55 (+0.57), EXEL: 5.40 (-0.01)
Exelixis, Inc. Earnings: Riding the Meteor
Brian Orelli, The Motley Fool - Motley Fool - 12 mins ago
Exelixis reported earnings on Tuesday, and as usual, the pipeline was much more important for the biotech than its revenue and profit. Exelixis results: The raw numbers Metric Q3 2015 Actuals Q3 2014 Actuals Growth (YOY)...
MRK: 53.03 (unch), BMY: 64.15 (+0.43), EXEL: 5.40 (-0.01)
6 Stocks That Could Double In 2016
Matthew Frankel, Selena Maranjian, Sean Williams, Dan Caplinger, Jason Hall, and Cheryl Swanson, The Motley Fool - Motley Fool - Sat Nov 14, 2:00PM CST
Source: 401kcalculator.org via Flickr . As long as most of your money is invested in high-quality, stable companies, there's absolutely nothing wrong with doing some speculating on companies with massive potential for gains. With that in mind,...
DDD: 8.75 (+0.23), CLF: 2.72 (-0.29), LL: 13.87 (-1.03), TWTR: 25.18 (-0.95), GTLS: 19.36 (+0.18), EXEL: 5.40 (-0.01)
Are Investors Nuts To Be Short These Stocks?
Todd Campbell, The Motley Fool - Motley Fool - Sat Nov 14, 8:01AM CST
Source: Flickr user stockmonkeys.com Healthcare stocks are among the most heavily shorted stocks on the market and the number of shares held short relative to shares outstanding for these three companies is downright stratospheric. Because...
ZIOP: 12.94 (-0.17), EXEL: 5.40 (-0.01), ATHN: 161.21 (-0.88)
Exelixis to Present at the Stifel 2015 Healthcare Conference on Tuesday, November 17
Business Wire - Thu Nov 12, 3:35PM CST
Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company's president and chief executive officer, will provide an overview of the company at Stifel's 2015 Healthcare Conference, taking place November 17-18 in New York. The Exelixis presentation is scheduled for 3:00 PM EST/12:00 PM PST on Tuesday, November 17, 2015.
EXEL: 5.40 (-0.01)
Exelixis (EXEL) Stock Dropped Following Earnings Release
at The Street - Wed Nov 11, 3:23PM CST
Exelixis (EXEL) shares closed trading down nearly double digits following mixed third quarter earnings results.
EXEL: 5.40 (-0.01)
Why Exelixis Shares Declined Today
Todd Campbell, The Motley Fool - Motley Fool - Wed Nov 11, 11:16AM CST
Source: Exelixis What: After reporting third quarter financials and receiving an FDA green light for a key drug prospect, shares in Exelixis slipped by up to 10% earlier today. So what: Exelixis has one drug on the market, and...
EXEL: 5.40 (-0.01)
The Zacks Analyst Blog Highlights: Gilead Sciences, Retrophin, Exelixis, Actelion and Enzo Biochem
Zacks Equity Research - Zacks Investment Research - Wed Nov 11, 8:30AM CST
The Zacks Analyst Blog Highlights: Gilead Sciences, Retrophin, Exelixis, Actelion and Enzo Biochem
ENZ: 4.50 (+0.14), GILD: 102.57 (-1.66), RTRX: 18.72 (+0.42), EXEL: 5.40 (-0.01)
Exelixis (EXEL) Stock Declines in After-Hours Trading on Quarterly Loss
at The Street - Tue Nov 10, 3:59PM CST
Exelixis (EXEL) stock is falling in after-hours trading after the company reported a wider than expected loss for the 2015 third quarter.
EXEL: 5.40 (-0.01)
Exelixis reports 3Q loss
Automated Insights - Tue Nov 10, 3:46PM CST
SOUTH SAN FRANCISCO, Calif. (AP) _ Exelixis Inc. (EXEL) on Tuesday reported a loss of $47.6 million in its third quarter.
EXEL: 5.40 (-0.01)
Exelixis Announces Third Quarter 2015 Financial Results and Provides Corporate Update
Business Wire - Tue Nov 10, 3:27PM CST
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2015 and provided an update on progress toward delivering upon its key 2015 corporate objectives and clinical development milestones.
EXEL: 5.40 (-0.01)
Daiichi Sankyo and Plexxikon Announce FDA Approval of Cobimetinib in Combination with Zelboraf® (vemurafenib) in Advanced Melanoma
PR Newswire - Tue Nov 10, 3:11PM CST
Daiichi Sankyo, Inc. and Plexxikon Inc., a member of the Daiichi Sankyo Group, today announced the U.S. Food and Drug Administration (FDA) approved cobimetinib, developed by Genentech, a member of the Roche Group, and Exelixis Inc., for the treatment of people with BRAF V600E or V600K mutation-positive unresectable or metastatic melanoma in combination with Zelboraf® (vemurafenib). Cobimetinib and Zelboraf are not used to treat melanoma with a normal BRAF gene. Cobimetinib in combination with Zelboraf will be co-promoted in the United States by Genentech, Daiichi Sankyo, Inc. and Exelixis. Cobimetinib will be available within two weeks.
EXEL: 5.40 (-0.01)
FDA Approves COTELLIC(TM) (Cobimetinib) for use in Combination with Vemurafenib to Treat Advanced Melanoma
Business Wire - Tue Nov 10, 12:37PM CST
--COTELLIC is expected to be available in the U.S. within two weeks -
EXEL: 5.40 (-0.01)
5 Biotech Stocks with Good Growth Prospects
Swarup Gupta - Zacks Investment Research - Tue Nov 10, 9:35AM CST
A variety of factors indicate that the growth potential for the sector remains undiminished
ENZ: 4.50 (+0.14), GILD: 102.57 (-1.66), SHPG: 203.58 (-2.36), UNH: 111.41 (-1.41), RTRX: 18.72 (+0.42), AMGN: 151.55 (+0.57), DYAX: 34.42 (+0.03), EXEL: 5.40 (-0.01)
What to Expect from Exelixis (EXEL) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Mon Nov 09, 2:50PM CST
Will Exelixis (EXEL) pull a surprise this earnings season?
AFMD: 6.04 (-0.21), CXRX: 33.10 (+4.56), EXEL: 5.40 (-0.01)
The Zacks Analyst Blog Highlights: Amazon.com, LendingTree, Dycom Industries, Exelixis and ZIOPHARM Oncology
Zacks Equity Research - Zacks Investment Research - Thu Nov 05, 8:30AM CST
The Zacks Analyst Blog Highlights: Amazon.com, LendingTree, Dycom Industries, Exelixis and ZIOPHARM Oncology
AMZN: 642.35 (-23.25), ZIOP: 12.94 (-0.17), TREE: 116.49 (-2.51), DY: 81.82 (-1.10), EXEL: 5.40 (-0.01)
5 Stocks That Doubled in 2015 -- And Keep Going Up
Zacks Equity Research - Zacks Investment Research - Wed Nov 04, 3:12PM CST
Despite the adversities playing spoilsport, there are a few stocks that have not only held the fort but have also crushed market estimates in 2015.
AMZN: 642.35 (-23.25), ZIOP: 12.94 (-0.17), TREE: 116.49 (-2.51), DY: 81.82 (-1.10), EXEL: 5.40 (-0.01)
Covered Call Alerts For Ambarella, Exelixis, Electronic Arts, Nabors Industries and Whole Foods Market Released By InvestorsObserver
PR Newswire - Wed Nov 04, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for AMBA, EXEL, EA, NBR and WFM.
WFM: 29.55 (-0.36), AMBA: 50.35 (-2.04), EA: 69.89 (-1.77), NBR: 9.25 (+0.03), EXEL: 5.40 (-0.01)
3 Biotech Stocks to Buy in November
Brian Feroldi, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Sun Nov 01, 12:20PM CST
Image Source TBIT via pixabay Well, that was fast. A month ago it seemed like biotech stocks couldn't do anything right. Shares of the iShares Nasdaq Biotechnology ETF , which holds a huge collection of biotech stocks, were pummeled over fears...
SGYP: 5.92 (+0.03), IRWD: 11.87 (+0.43), ALXN: 166.44 (+0.31), IBB: 323.64 (+3.53), EXEL: 5.40 (-0.01)
United Therapeutics Beats on Q3 Earnings, Revenues
Arpita Dutt - Zacks Investment Research - Wed Oct 28, 11:18AM CDT
United Therapeutics' (UTHR) third quarter results were better-than-expected with the company's products performing well.
MDT: 74.46 (+0.25), UTHR: 146.79 (+0.65), AMGN: 151.55 (+0.57), EXEL: 5.40 (-0.01)
Agenus Q3 Loss Wider than Expected, Pipeline in Focus
Zacks Equity Research - Zacks Investment Research - Wed Oct 28, 10:50AM CDT
Agneus (AGEN) reported wider-than-expected loss.
AGEN: 4.63 (+0.11), AMGN: 151.55 (+0.57), EXEL: 5.40 (-0.01)
